奥马珠单抗加速症状驱动的多食物 OIT (BOOM)
一项为期 15 个月的双盲随机对照试验，比较两种剂量的奥马珠单抗与安慰剂的 20 周加速 6 至 25 岁多种食物过敏受试者的症状驱动口服免疫治疗计划
This study will determine the dose-related efficacy of a 20-week treatment of omalizumab started 8 weeks before the onset of a symptom-driven multi-food oral immunotherapy (OIT) protocol at decreasing time to OIT maintenance dose. Two dosages of omalizumab will be compared to placebo during an oral immunotherapy protocol for three simultaneous food allergens.
研究概览
地位
详细说明
This is a phase 2b, multi-center randomized controlled trial comparing 2 doses of omalizumab to placebo in subjects 6 to 25 years old with multiple food allergies undergoing a symptom-driven multi-food OIT protocol.
Subjects will undergo a screening period involving a DBPCFC to a mix of three allergens which will determine their eligibility and eliciting dose.
Eligible subjects will be randomized to one of 2 omalizumab dosages or placebo at a ratio of 2:2:1 for a total period of 20 weeks.
They will undergo initial food escalation (IFE) to determine their starting food treatment mix dose for three simultaneous food allergens after a pre-treatment period of 8 weeks with the study drug.
Subjects will undergo up-dosing OIT visits at the clinic every two weeks, until a maintenance dose of 1500mg of protein (500mg per food) is reached (primary endpoint).
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G 1X8
- The Hospital for Sick Children
-
-
Quebec
-
Montreal、Quebec、加拿大、H3T 1C5
- Centre Hospitalier Universitaire Sainte-Justine
-
Sherbrooke、Quebec、加拿大、J1H 5N4
- CIUSSS de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CHUS)
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion criteria:
- Male or female subjects 6 to 25 years old at screening visit.
- History of IgE-mediated allergy to at least three foods within the following list: peanut, milk, egg, wheat, oat, soy, barley, rye, buckwheat, hazelnut, pecan, cashew, pistachio, almond, walnut and sesame.
- Subjects currently following a strict avoidance of these three foods.
- Positive SPT with a largest wheal diameter ≥ 6 mm to all three foods.
- Food-specific IgE level greater than 15 kU/L for all three foods
- Positive DBPCFC to treatment food mix with an eliciting dose ≤ 300 mg of total food protein.
- Signed informed consent and assent.
Exclusion criteria
- Subjects reacting objectively to the placebo during the screening DBPCFC.
- Severe asthma as defined by GINA 201948.
- Active or past confirmed eosinophilic oesophagitis.
- Subject currently under allergen immunotherapy.
- Subject/parent with excessive anxiety unlikely to cope with study conditions as per investigator's opinion.
- Subject/parent unwillingness to comply with study requirements.
- Subject unwillingness to ingest a daily food dose of up to 1500 mg of allergen protein.
- Inability to discontinue anti-histamine medication prior to study procedures.
- Known allergy to omalizumab or its excipients.
- Known allergy to components of the placebo food treatment mix that cannot be substituted without interfering with the blind (e.g.: dates, banana, chocolate syrup)
- Use of immunosuppression or immunomodulatory drug (including omalizumab) or food oral immunotherapy or investigational treatment or procedure within 1 year.
- Relative contraindication or inability to use epinephrine auto-injector.
- Subjects receiving beta-blockers or angiotensin converting-enzyme (ACE) inhibitors.
- Pregnancy or lactation for the duration of the study.
- Any condition that is not compatible with the study treatment or procedures as per investigator judgment.
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Omalizumab 16 mg/kg
Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks. Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug. |
Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period. Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein. |
|
实验性的：Omalizumab 8 mg/kg
Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks. Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug. |
Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein. Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period. |
|
安慰剂比较：Placebo
Participants will receive placebo doses for 20 weeks. The doses will be injected every 2 or 4 weeks depending on the weight of the participant. Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug. |
Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein. Participants will receive placebo for 8 weeks prior to the initiation of oral immunotherapy and 12 weeks after for a total of 20 weeks including a taper period. |
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To determine the efficacy of omalizumab at decreasing time-to-maintenance during a symptom-driven multi-food OIT protocol.
大体时间：Assessed up to 52 weeks after IFE
|
Time from IFE to target multi-food protein maintenance dose of 1500 mg of total food protein |
Assessed up to 52 weeks after IFE
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in reactivity threshold to food treatment mix after pre-treatment with study drug.
大体时间：Measured 8 weeks after starting investigational product
|
Measured as the amount of food allergen eliciting an objective allergic reaction on double-blinded oral food challenge or initial food escalation. |
Measured 8 weeks after starting investigational product
|
|
Average up-dosing speed while on study drug.
大体时间：From week 0 to week 12 post IFE
|
Average of (log of escalation %)/(days since last escalation) for all escalation visits while on study drug |
From week 0 to week 12 post IFE
|
|
Mean cumulative function of allergic adverse events attributable to food dosing throughout the trial.
大体时间：For one year following IFE
|
AEs will be captured using the daily dosing diary throughout the trial, including during maintenance. Any systemic reaction having occurred since the last visit will be reviewed and graded by the investigator according to the CoFAR grading system. |
For one year following IFE
|
|
Rate of treatment failure
大体时间：At any time during the 12-month OIT phase
|
Subject which stop daily ingestion of food treatment mix, prior to achieving study maintenance dose, for a period of 14 days or more |
At any time during the 12-month OIT phase
|
合作者和调查者
合作者
调查人员
- 首席研究员：Philippe Bégin, MD, PhD、St. Justine's Hospital
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.